Efficacy of Velpatasvir Sofosbovir alone Versus in Combination with Ribavarin in Cirrhotic Patients with Hepatitis C
DOI:
https://doi.org/10.70749/ijbr.v3i5.1153Abstract
Background: Chronic Hepatitis C (HCV) infection is a major cause of liver cirrhosis and its complications. Direct-acting antivirals (DAAs) such as sofosbuvir and velpatasvir have shown high efficacy in treating HCV, but the additional role of ribavirin in combination therapy remains uncertain, particularly in cirrhotic patients. Objective: This study compares the efficacy and safety of sofosbuvir/velpatasvir alone versus in combination with ribavirin in cirrhotic patients with HCV. Methods: This randomized controlled trial was conducted at the Department of Medicine, CMH Kharian. A total of 120 patients with chronic HCV-related cirrhosis (Child-Pugh B or C) were enrolled and randomly assigned to two treatment groups: Group A (sofosbuvir/velpatasvir) and Group B (sofosbuvir/velpatasvir/ribavirin). Both groups received treatment for 12 weeks, and patients were followed up for 12 weeks post-treatment. Results: SVR12 was achieved in 89% of patients in Group A and 92% of patients in Group B. No significant difference was found between the two groups (p = 0.68). Treatment failure occurred in 5% of Group A and 6.7% of Group B patients, while relapse rates were 3.3% and 5%, respectively. The incidence of adverse events was higher in Group B (40%) compared to Group A (28.3%), with the most common side effects being nausea, headache, and fatigue. Severe adverse events, including treatment discontinuation, were reported in 3.3% of patients in Group B but were absent in Group A. Conclusion: Sofosbuvir/velpatasvir alone is as effective as the combination of sofosbuvir/velpatasvir and ribavirin in achieving SVR12 in cirrhotic patients with HCV. The addition of ribavirin did not significantly improve efficacy but was associated with a higher incidence of adverse events.
Downloads
References
Liu, C., Chen, C., Su, W., Liu, C., Lo, C., Huang, K., Chen, J., Tseng, K., Chang, C., Peng, C., Shih, Y., Huang, C., Kao, W., Yang, S., Tsai, M., Wu, J., Chen, P., Su, P., Hwang, J., … Kao, J. (2021). Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis. Clinical and Molecular Hepatology, 27(4), 575-588. https://doi.org/10.3350/cmh.2021.0155
Margusino-Framiñán, L., Cid-Silva, P., Rotea-Salvo, S., Mena-de-Cea, Á., Suárez-López, F., Vázquez-Rodríguez, P., Delgado-Blanco, M., Sanclaudio-Luhia, A. I., Martín-Herranz, I., & Castro-Iglesias, Á. (2020). Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients. European Journal of Hospital Pharmacy, 27(e1), e41-e47. https://doi.org/10.1136/ejhpharm-2019-002060
Fathi, H., Clark, A., Hill, N. R., & Dusheiko, G. (2017). Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: A large-scale systematic review. BMC Infectious Diseases, 17(1). https://doi.org/10.1186/s12879-017-2820-z
Abbas, Z., & Abbas, M. (2020). The cost of eliminating hepatitis C in Pakistan. The Lancet Global Health, 8(3), e323-e324. https://doi.org/10.1016/s2214-109x(20)30036-x
Arshad, A., & Ashfaq, U. A. (2017). Epidemiology of hepatitis C infection in Pakistan: Current estimate and major risk factors. Critical Reviews in Eukaryotic Gene Expression, 27(1), 63-77. https://doi.org/10.1615/critreveukaryotgeneexpr.2017018953
Haqqi, A., Munir, R., Khalid, M., Khurram, M., Zaid, M., Ali, M., Shah, Z. H., Ahmed, H., & Afzal, M. S. (2019). Prevalence of hepatitis C virus genotypes in Pakistan: Current scenario and review of literature. Viral Immunology, 32(9), 402-413. https://doi.org/10.1089/vim.2019.0058
Negro, F. (2019). Natural history of hepatic and extrahepatic hepatitis C virus diseases and impact of interferon-free HCV therapy. Cold Spring Harbor Perspectives in Medicine, 10(4), a036921. https://doi.org/10.1101/cshperspect.a036921
Ahmed, R., Kareem, R., Venkatesan, N., Botleroo, R. A., Ogeyingbo, O. D., Bhandari, R., Gyawali, M., & Elshaikh, A. O. (2021). Sofosbuvir/Velpatasvir - A promising treatment for chronic hepatitis C virus infection. Cureus. https://doi.org/10.7759/cureus.17237
Cheng, P. N., Mo, L. R., Chen, C. T., Chen, C. Y., Huang, C. F., Kuo, H. T., ... & TACR investigators. (2022). Sofosbuvir/velpatasvir for hepatitis C virus infection: real-world effectiveness and safety from a nationwide registry in Taiwan. Infectious Diseases and Therapy, 11(1), 485-500. https://doi.org/10.1007/s40121-021-00576-7
Heo, Y., & Deeks, E. D. (2018). Sofosbuvir/Velpatasvir/Voxilaprevir: A review in chronic hepatitis C. Drugs, 78(5), 577-587. https://doi.org/10.1007/s40265-018-0895-5
Ahmed, H., Abushouk, A. I., Attia, A., Gadelkarim, M., Gabr, M., Negida, A., & Abdel-Daim, M. M. (2018). Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: A systematic review and meta-analysis. Journal of Infection and Public Health, 11(2), 156-164. https://doi.org/10.1016/j.jiph.2017.09.004
Loo, J. H., Xu, W. X., Low, J. T., Tay, W. X., Ang, L. S., Tam, Y. C., Thurairajah, P. H., Kumar, R., & Wong, Y. J. (2022). Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis. World Journal of Hepatology, 14(6), 1248-1257. https://doi.org/10.4254/wjh.v14.i6.1248
Izumi, N., Takehara, T., Chayama, K., Yatsuhashi, H., Takaguchi, K., Ide, T., Kurosaki, M., Ueno, Y., Toyoda, H., Kakizaki, S., Tanaka, Y., Kawakami, Y., Enomoto, H., Ikeda, F., Jiang, D., De-Oertel, S., McNabb, B. L., Camus, G., Stamm, L. M., … Mizokami, M. (2018). Sofosbuvir–velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatology International, 12(4), 356-367. https://doi.org/10.1007/s12072-018-9878-6
Shah, I., Ahmad, W., Qadir, A., Muhammad, I., Islam, M., Shah, M., Jan, N., & Anjum, S. (2021). Efficacy and safety of Sofosbuvir and Velpatasvir combination for the treatment of chronic hepatitis C in patients with or without cirrhosis. Cureus. https://doi.org/10.7759/cureus.19768
Esteban, R., Pineda, J. A., Calleja, J. L., Casado, M., Rodríguez, M., Turnes, J., Morano Amado, L. E., Morillas, R. M., Forns, X., Pascasio Acevedo, J. M., Andrade, R. J., Rivero, A., Carrión, J. A., Lens, S., Riveiro-Barciela, M., McNabb, B., Zhang, G., Camus, G., Stamm, L. M., … Buti, M. (2018). Efficacy of Sofosbuvir and Velpatasvir, with and without Ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis. Gastroenterology, 155(4), 1120-1127.e4. https://doi.org/10.1053/j.gastro.2018.06.042
Flamm, S., Lawitz, E., Borg, B., Charlton, M., Landis, C., Reddy, K. R., Shiffman, M., Alsina, A., Chang, C., Ravendhran, N., Hernandez, C., Hézode, C., Scherbakovsky, S., Mercier, R., & Samuel, D. (2023). Efficacy and safety of Sofosbuvir/Velpatasvir plus Ribavirin in patients with hepatitis C virus-related decompensated cirrhosis. Viruses, 15(10), 2026. https://doi.org/10.3390/v15102026
European Association for the Study of the Liver. (2023). Corrigendum to ‘EASL recommendations on treatment of hepatitis C: Final update of the series’ [J Hepatol 73 (2020) 1170–1218]. Journal of Hepatology, 78(2), 452. https://doi.org/10.1016/j.jhep.2022.10.006
Takehara, T., Sakamoto, N., Nishiguchi, S., Ikeda, F., Tatsumi, T., Ueno, Y., Yatsuhashi, H., Takikawa, Y., Kanda, T., Sakamoto, M., Tamori, A., Mita, E., Chayama, K., Zhang, G., De-Oertel, S., Dvory-Sobol, H., Matsuda, T., Stamm, L. M., Brainard, D. M., … Kurosaki, M. (2018). Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: An open-label phase 3 trial. Journal of Gastroenterology, 54(1), 87-95. https://doi.org/10.1007/s00535-018-1503-x
Mangia, A., Milligan, S., Khalili, M., Fagiuoli, S., Shafran, S. D., Carrat, F., Ouzan, D., Papatheodoridis, G., Ramji, A., Borgia, S. M., Wedemeyer, H., Losappio, R., Pérez‐Hernandez, F., Wick, N., Brown, R. S., Lampertico, P., Doucette, K., Ntalla, I., Ramroth, H., … Turnes, J. (2020). Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. Liver International, 40(8), 1841-1852. https://doi.org/10.1111/liv.14537
Mangia, A., Lawitz, E., Gane, E., Conway, B., Ruane, P., Abergel, A., Mcnabb, B., Osinusi, A., Chen, F., Dvory-Sobol, H., Brainard, D., Subramanian, M., Leggett, B., Panero, J. L., Agarwal, K., Younes, Z., & Muir, A. (2018). Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with sofosbuvir-based regimens. Journal of Hepatology, 68, S67-S68. https://doi.org/10.1016/s0168-8278(18)30356-8
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
